Baricitinib
As of the edition of 20 October 2026, Baricitinib is a small molecule: marketed, first approved in 2017 (EU); acts on JAK1 and JAK2; US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Olumiant
- First approved
- 13 February 2017 (EU)
- Approvals on record
- 13 in 4 regions
- Holder of the most recent approval
- Eli Lilly; 2 holders in all
- Registered trials
- 157, 15 stopped early
- Disease areas
- Skin and connective tissue; Immune system; Bones, joints and muscles; Infections; Lungs and airways; Inherited and neonatal
US protection
US protection ends in 2032.
The last listed US drug-substance patent ends in 2032. The application that gives this date is held by Eli Lilly.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product3 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 3 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Baricitinib.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 16 | 5 | 5 | 0 |
| Phase 1 | 22 | 20 | 2 | 0 |
| Phase 2 | 53 | 21 | 18 | 4 |
| Phase 3 | 54 | 22 | 15 | 10 |
| Phase 4 | 12 | 4 | 5 | 1 |
| All trials | 157 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Applicant and Lead sponsor of trials | 2013 to now |